Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cerebral Protection in Transcatheter Aortic Valve Replacement

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Claret Medical
ClinicalTrials.gov Identifier:
NCT02214277
First received: August 8, 2014
Last updated: May 23, 2016
Last verified: May 2016
  Purpose
The Sentinel System will be a safe and effective method for capturing and removing embolic material (thrombus/debris) during transcatheter aortic valve replacement in order to reduce the ischemic burden in the cerebral anterior circulation.

Condition Intervention
Severe Symptomatic Calcified Native Aortic Valve Stenosis
Device: Cerebral Protection System-The SENTINEL System with TAVR
Device: TAVR

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL Study

Resource links provided by NLM:


Further study details as provided by Claret Medical:

Primary Outcome Measures:
  • Primary Efficacy Endpoint [ Time Frame: Day 4-7 Post-Procedure ]

    Reduction in median total new lesion volume in protected territories between the Imaging Arms (Test and Control Group) as assessed by DW-MRI at Day 4-7 post-procedure.

    • Total new lesion volume is defined as the sum of all diffusion-positive new cerebral lesions in post-procedural DW-MRI relative to the pre-TAVR DW-MRI scans.
    • Protected territories are defined as brain territories uniquely perfused by the vessels protected by the Sentinel System, namely the left and right carotid arteries, and the right vertebral artery.


Other Outcome Measures:
  • Primary Safety Endpoint [ Time Frame: 30 Days Post-Procedure ]
    Occurrence of all Major Adverse Cardiac and Cerebrovascular Events (MACCE) at 30 days compared to a historical performance goal.


Enrollment: 363
Study Start Date: September 2014
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Test Arm Device: Cerebral Protection System-The SENTINEL System with TAVR
Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
Other Names:
  • Cerebral Protection System: The SENTINEL System
  • TAVR Device: Edwards SAPIEN THV or Edwards SAPIEN XT
Active Comparator: Control Arm Device: TAVR
Other Name: TAVR: Edwards SAPIEN THV or Edwards SAPIEN XT
Safety Arm Device: Cerebral Protection System-The SENTINEL System with TAVR
Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
Other Names:
  • Cerebral Protection System: The SENTINEL System
  • TAVR Device: Edwards SAPIEN THV or Edwards SAPIEN XT

Detailed Description:

The Sentinel™ Cerebral Protection System is indicated for use as an embolic capture and retrieval system intended to reduce the ischemic burden in the cerebral anterior circulation while performing transcatheter aortic valve replacement.

The objective of this study is to assess the safety and efficacy of the Claret Medical Sentinel Cerebral Protection System used for embolic protection during Transcatheter Aortic Valve Replacement (TAVR) compared to TAVR standard of care (without embolic protection).

The study population is comprised of subjects with severe symptomatic calcified native aortic valve stenosis who meet the commercially approved indications for TAVR with the Edwards SAPIEN THV or SAPIEN XT and comply with the inclusion/exclusion criteria.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Approved indications for commercially available Edwards SAPIEN Transcatheter Heart Valve, model 9000TFX or SAPIEN XT, model 9300TFX meeting one of the three sub-criteria below:

    SAPIEN

    1. transfemoral delivery in subjects with severe symptomatic calcified native aortic valve stenosis without severe aortic insufficiency and with ejection fraction >20% who have been examined by a heart team including an experienced cardiac surgeon and a cardiologist and found to either be:

      1. inoperable and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis; or
      2. be operative candidates for aortic valve replacement but who have a Society of Thoracic Surgeons predicted operative risk score >8% or are judged by the heart team to be at a 15% risk of mortality for surgical aortic valve replacement.

      or

    2. transapical delivery in subjects with severe symptomatic calcified native aortic valve stenosis without severe aortic insufficiency and with ejection fraction > 20% who have been examined by a heart team including an experienced cardiac surgeon and a cardiologist and found to be operative candidates for aortic valve replacement but who have a Society of Thoracic Surgeons operative risk score 8% or are judged by the heart team to be at a 15% risk of mortality for surgical aortic valve replacement.

      SAPIEN XT (Transfemoral or Transapical only)

    3. in patients with symptomatic heart disease due to severe native calcific aortic stenosis (aortic valve area ≤ 1.0 cm2 or aortic valve area index ≤ 0.6 cm2/m2, a mean aortic valve gradient of ≥ 40 mmHg, or a peak aortic-jet velocity of ≥ 4.0 m/s), and with native anatomy appropriate for the 23, 26, or 29 mm valve system, who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., Society of Thoracic Surgeons operative risk score ≥8% or at a ≥15% risk of mortality at 30 days).
  2. Compatible left common carotid artery (6.5 - 10 mm) and brachiocephalic artery (9 - 15 mm) diameters without significant stenosis (> 70%) as determined by Multi-Slice Computed Tomography (MSCT) scan or equivalent imaging modality
  3. The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visit
  4. The subject or the subject's legal representative has been informed of the nature of the trial, agrees to its provisions and has provided written informed consent as approved by the IRB of the respective clinical site

Exclusion Criteria:

General

  1. Vasculature in the right extremity precluding 6Fr sheath radial or brachial access
  2. Inadequate circulation to the right extremity as evidenced by signs of artery occlusion (modified Allen's test) or absence of radial/brachial pulse
  3. Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity vasculature
  4. Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment
  5. Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified
  6. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+)
  7. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease)
  8. Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe (greater than 3+) mitral insufficiency
  9. Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy
  10. Hemodynamic instability requiring inotropic support or mechanical heart assistance.
  11. Need for emergency surgery for any reason
  12. Hypertrophic cardiomyopathy with or without obstruction
  13. Severe ventricular dysfunction with LVEF ≤20%
  14. Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation
  15. Symptomatic or asymptomatic severe occlusive carotid disease requiring concomitant CEA/stenting
  16. Subject has undergone carotid stenting or carotid endarterectomy within the previous 6 weeks
  17. Active peptic ulcer or upper GI bleeding within the prior 3 months
  18. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or clopidogrel, or sensitivity to contrast media, which cannot be adequately pre-medicated
  19. Recent (within 6 months) CVA or a TIA
  20. Renal insufficiency (creatinine > 3.0 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening
  21. Life expectancy < 12 months due to non-cardiac co-morbid conditions
  22. Subjects in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion
  23. Subjects who have active bacterial endocarditis or other active infections
  24. Currently participating in an investigational drug or another device study
  25. Subjects who have a planned treatment with any other investigational device or procedure during the study follow-up period (90 days)
  26. Subject with planned concomitant surgical or transcatheter ablation for Atrial Fibrillation during the study follow-up period (90 days)
  27. Any subject with a balloon valvuloplasty (BAV) within 30 days of the procedure

    Neurologic

  28. Subject had active major psychiatric disease
  29. Subject has severe visual, auditory, or learning impairment and who are unable to comprehend English and therefore unable to be consented for the study
  30. Subjects with neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities

    Angiographic

  31. Excessive tortuosity in the right radial/brachial/subclavian artery preventing Sentinel System access and insertion
  32. Subject whose brachiocephalic or left carotid artery reveals significant stenosis, calcification, ectasia, dissection, or aneurysm at the ostium or within 3 cm of the ostium

    Magnetic Resonance Imaging

  33. Subject Body Mass Index (BMI) precluding imaging in scanner
  34. Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure)
  35. Planned implantation of a pacemaker or defibrillator implantation after TAVR
  36. Claustrophobia
  37. Known allergy to gadolinium or contrast agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02214277

Locations
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States
United States, District of Columbia
Washington Hospital Center
Washington DC, District of Columbia, United States
United States, Florida
Morton Plant Hospital
Clearwater, Florida, United States
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States
United States, Missouri
Barnes-Jewish Hospital
St Louis, Missouri, United States
United States, New York
Icahn School of Medicine at Mount Sinai
New York City, New York, United States
Weill Cornell Medical Center
New York City, New York, United States
Columbia University Medical Center
New York, New York, United States
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Texas
UT Houston / Memorial Hermann
Houston, Texas, United States
United States, Virginia
UVA Advanced Cardiac Valve Center
Charlottesville, Virginia, United States
United States, Washington
UW Medical Center
Seattle, Washington, United States
Sponsors and Collaborators
Claret Medical
Investigators
Principal Investigator: Susheel Kodali, MD Columbia University
Principal Investigator: Samir Kapadia, MD The Cleveland Clinic
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Claret Medical
ClinicalTrials.gov Identifier: NCT02214277     History of Changes
Other Study ID Numbers: CP-10836
Study First Received: August 8, 2014
Last Updated: May 23, 2016

Keywords provided by Claret Medical:
Embolic Protection
Edwards SAPIEN THV
Edwards SAPIEN XT
TAVR
Transfemoral
Transapical
Heart Valve Diseases
Heart Diseases
TAVI
Aortic Stenosis
Aortic Valve
Transcatheter Heart Valve

Additional relevant MeSH terms:
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction

ClinicalTrials.gov processed this record on May 25, 2017